Clinical trial
Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast…
NCT00005991 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005991 |
|---|---|
| Title | Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer |
| Official title | Phase I/II Study of Gemcitabine and Doxil Combination Chemotherapy in Patients With Advanced Solid Tumors (Phase I)/Breast Cancer (Phase II) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride |
| Enrollment | 76 |
| Start date | Aug 25, 1997 |
| Primary completion | Feb 14, 2003 |
| Completion | Feb 14, 2003 |
| First posted | Feb 25, 2004 |
| Last update posted | Nov 14, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: